All
Development of EO-3021 Discontinued for Gastric and GEJ Cancers
Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.
Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer
In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.
Gene Expression Testing and Targeted Therapies in Breast Cancer Care
Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
Painting an Accurate Portrait of Breast Cancer Survivorship
As a breast cancer survivor, I feel it is incumbent upon me to give an accurate picture of cancer to others, particularly newly diagnosed patients.
Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression
Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.
FDA Grants Compassionate Use Treatment to Namodenoson in Pancreatic Cancer
The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.
Disparities in Breast Cancer Care, Genomic Insights and Early Detection
Dr. Regina Hampton highlighted unmet needs in black women with breast cancer and details how genomic information can drive effective treatment options.
Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
Understanding Genetic and Genomic Testing in Breast Cancer
Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.
Investigating Quality of Life and Treatment Adherence in Kidney Cancer
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Nominations Open for the End Brain Cancer Initiative’s 2025 National Patient Disease Education Initiative and HOPE Award
Life Lessons I Learned After My Colon Cancer Diagnosis
After being diagnosed with colon cancer, I learned the life-changing lessons of self-love, stepping out of my comfort zone and embracing positive thinking.
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain
The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.
The Importance of Spotting Endometrial Cancer
Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
First relapse in multiple myeloma: the patient perspective
The Role of Circulating Tumor DNA in Breast Cancer Monitoring
Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.
Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.
Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.
Registration Open for the 2025 Know All Your Treatment Options Webinar Hosted by the End Brain Cancer Initiative
A Picture is Worth Ten Thousand Words When it Comes to Cancer
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.
Precision Radiation Therapy Makes Strides in Colorectal Cancer Care
Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.
SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds
Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
Why It’s Important to Have Hard Conversations in Breast Cancer Care
CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.
Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.
Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype
Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.
PSMA-PET Improves Detection of Metastases in High-Risk Prostate Cancer
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging.
